Key Takeaways:
Implied volatility on Halozyme Therapeutics Inc. options surged 26% on May 26, signaling options traders are bracing for a significant price swing in the $8.2 billion biotechnology company.
"Elevated implied volatility typically precedes a catalyst event such as an earnings release, trial data readout, or regulatory decision," said Priya Mehta, equity market structure analyst at Edgen. "The magnitude of the move in HALO options suggests the market is pricing in a binary outcome."
Halozyme, which develops enzyme technologies that enable subcutaneous drug delivery for large-molecule therapies, has partnerships with Roche, Bristol Myers Squibb, and Pfizer. The company's ENHANZE drug-delivery platform is used in approved products including Roche's Phesgo and Bristol Myers' Opdivo. The options activity comes ahead of the company's next earnings report, expected in late July, and follows a 12% gain in HALO shares year-to-date through May 23.
The implied volatility surge puts HALO in the 95th percentile of its trailing one-year range, a level that has historically preceded outsized stock moves. Elevated options premiums suggest the market anticipates a move of at least 8% in either direction over the next 30 days, based on at-the-money straddle pricing. The stock closed at $67.42 on May 23, near its 50-day moving average, after trading in a range of $52.18 to $78.44 over the past 12 months. Traders will watch for any company filings or press releases that could explain the positioning buildup.
This article is for informational purposes only and does not constitute investment advice.
